Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
615 JPY | -0.65% |
|
+1.49% | -47.53% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-47.53% | 478M | - | ||
+55.55% | 816B | C+ | ||
+40.88% | 634B | B | ||
-6.83% | 351B | C+ | ||
+17.15% | 323B | B- | ||
+7.09% | 293B | C+ | ||
+13.60% | 238B | B+ | ||
+1.51% | 222B | A+ | ||
+13.55% | 218B | B- | ||
+7.87% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4552 Stock
- Ratings JCR Pharmaceuticals Co., Ltd.